Trials / Unknown
UnknownNCT03540992
Development of Diagnostic and Treatment Strategy for Resistant Hypertension
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 780 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is a registry study to examine the clinical features, blood pressure control rate, and clinical prognosis of resistant hypertension in Koreans. This study will register patients with resistance hypertension in eight tertiary hospitals in Korea and follow up them for three years. The prognosis will be analysed according to etiologies, achieved blood pressure, and types of antihypertensive medication.
Detailed description
This study will enroll hypertensive patients who are in treatment or those who are referred from primary clinic based on inclusion or exclusion criteria. Basic clinical information, compliance with antihypertensive medications, concomitant use of other medications will be investigated and all patients will perform 24-hr ambulatory blood pressure measurement. Screening for renal artery stenosis and primary aldosteronism will be conducted. Office blood pressure will be taken every 3-6 months. Home blood pressure measurement and 24-hr ambulatory blood pressure measurement will be performed every year. The primary outcome is the newly developed MACE during the follow-up period. The secondary outcomes are newly developed target organ damage (LVH confirmed by echocardiography or EKG, carotid femoral PWV≥ 12m/s, microalbuminuria (Urine albumin-creatinine ratio ≥30 mg/g)) and decline of renal function (doubling of serum creatinine, dialysis). The follow-up period is 3 years.
Conditions
Timeline
- Start date
- 2018-02-14
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2018-05-30
- Last updated
- 2018-05-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03540992. Inclusion in this directory is not an endorsement.